MIST: Milestone Pharmaceuticals Inc. Stock

by  •  • Comments Off on MIST: Milestone Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 77.77
Enterprise Value ($M) 116.04
Book Value ($M) 31.98
Book Value / Share 0.60
Price / Book 2.43
NCAV ($M) 30.11
NCAV / Share 0.57
Price / NCAV 2.58

Profitability (mra)
Return on Invested Capital (ROIC) -0.57
Return on Assets (ROA) -0.50
Return on Equity (ROE) -1.20

Liquidity (mrq)
Quick Ratio 19.13
Current Ratio 19.13

Balance Sheet (mrq) ($M)
Current Assets 87.36
Assets 89.23
Liabilities 57.25
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.00
Operating Income -61.10
Net Income -59.69
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -46.42
Cash from Investing 4.76
Cash from Financing 47.79

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
07-16 13D/A Alta Fundamental Advisers LLC 4.99 59.07
02-14 13G/A Rtw Investments, Lp 9.99 -22.25
02-14 13G/A Venrock Healthcare Capital Partners III, L.P. 2.80 -58.12
02-09 13G/A Goldman Sachs Group Inc 4.10 -50.57
01-29 13G/A Integrated Core Strategies (us) Llc 5.20 -21.15
01-24 13G/A BlackRock Inc. 9.80 89.30

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRAN
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-09-09 83,541 240,378 34.75
2024-09-06 39,027 228,112 17.11
2024-09-05 53,136 166,878 31.84
2024-09-04 37,568 234,753 16.00

(click for more detail)

Similar Companies
MDGL – Madrigal Pharmaceuticals, Inc. MGNX – MacroGenics, Inc.
MGTX – MeiraGTx Holdings plc MLYS – Mineralys Therapeutics, Inc.
MNMD – Mind Medicine (MindMed) Inc.


Financial data and stock pages provided by
Fintel.io